26710 Federal Register / Vol. 74, No. 105 / Wednesday, June 3, 2009 / Notices 

Inventors: Thomas P. Conrads (NCI) et 

al. 

Relevant Publications 

1. BL Hood, MM Darfler, TG Guiel, B 

Furusato, DA Lucas, BR Ringeisen, IA 

Sesterhenn, TP Conrads, TD Veenstra, 

DB Krizman. Proteomic analysis of 

formalin-fixed prostate tissue. Mol Cell 

Proteomics 2005 Nov;4(11):1741–1753. 

2. DA Prieto, BL Hood, MM Darfler, 

TG Guiel, DA Lucas, TP Conrads, TD 

Veenstra, DB Krizman. Liquid tissueTM: 

proteomic profiling of formalin fixed 

tissues. Biotechniques 2005 Jun;38:S32– 

S35. 

3. DS Kirkpatrick, SA Gerber, SP Gygi. 

The absolute quantification strategy: A 

general procedure for the quantification 

of proteins and post-translational 

modifications. Methods 2005 

Mar;35(3):265–273. 

4. AM Hawkridge et al. Quantitative 

mass spectral evidence for the absence 

of circulating brain natriuretic peptide 

(BNP–32) in severe human heart failure. 

Proc Natl Acad Sci USA 2005 Nov 

29;102(48):17442–17447. 

5. L Anderson and CL Hunter. 

Quantitative mass spectrometric MRM 

assays for major plasma proteins. Mol 

Cell Proteomics 2006 Apr;5(4):573–588. 

Patent Status: PCT Application No. 

PCT/US2007/003478 filed 4 Sep 2008 

(HHS Reference No. E–204–2006/0– 

PCT–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Whitney Hastings; 

301–451–7337; hastingw@mail.nih.gov. 

Tools To Identify Candidates for 

Effective Cancer Therapy: Antibodies to 

Human Asparagine Synthetase 

Description of Technology: Scientists 

at the National Institutes of Health (NIH) 

have developed peptide-specific 

polyclonal antibodies against human 

asparagine synthetase (ASNS), the 

enzyme that forms asparagine from 

aspartate using ATP. ASNS serves as a 

key biomarker for acute lymphoblastic 

leukemia (ALL) and other malignancies 

because these cancer cells express little 

or no ASNS compared to normal cells. 

As a result, these leukemia cells must 

acquire asparagine from the bloodstream 

to survive and proliferate to form 

tumors. Patients with ALL can be 

treated with L-asparaginase (L–ASP) to 

break down asparagine in the body and 

starve leukemia cells by preventing 

them from acquiring asparagine. The 

anti-ASNS antibodies could be used to 

detect ASNS levels in patient samples to 

help select patients that could benefit 

from L–ASP therapy. Studies at the NIH 

have shown that L–ASP therapy may 

prove to be a useful treatment for other 

types of cancer besides leukemia. 

Applications 

• Diagnostic tool to detect levels of 

asparagine synthetase (ASNS) in human 

samples to identify cancer patients that 

can benefit from L-asparaginase (L–ASP) 

treatment. 

• Screening tool to identify other 

cancer cell types treatable by L–ASP 

therapy, such as ovarian cancer cells, 

which show diminished ASNS levels. 

• Research tool to quantitate levels of 

ASNS in laboratory procedures, 

including various immunoassays, flow 

cytometry, and tissue sample analysis. 

Advantages: These antibodies have 

been validated in immunoassays that 

showed that ASNS expression in a 

strong predictor of L–ASP efficacy in 

NCI–60 ovarian cancer cell lines. 

Inventors: Paul K. Goldsmith et al. 

(NCI). 

Relevant Publications 

1. PL Lorenzi et al. Asparagine 

synthetase as a causal, predictive 

biomarker for L-asparaginase activity in 

ovarian cancer cells. Mol Cancer Ther. 

2006 Nov;5(11):2613–2623. 

2. KJ Bussey et al. Integrating data on 

DNA copy number with gene expression 

levels and drug sensitivities in the NCI– 

60 cell line panel. Mol Cancer Ther. 

2006 Apr;5(4):853–867. 

3. PL Lorenzi et al. Asparagine 

synthetase as a predictive biomarker for 

L-asparaginase activity in ovarian 

cancer cells. Mol Cancer Ther. 2008 

Oct;7(10):3123–3128. 

Patent Status: HHS Reference No. E– 

101–2006/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing under a Biological Materials 

License Agreement. 

Licensing Contact: Samuel E. Bish, 

Ph.D.; 301–435–5282; 

bishse@mail.nih.gov. 

Mouse Model With Targeted Disruption 

of the Neurofibromatosis Type-1 (Nf1) 

Gene 

Description of Technology: This 

invention relates to a mouse model 

having a targeted disruption of the 

neurofibromatosis type-1 (NF1) gene. 

The neurofibromatosis (NF1) gene 

shows significant homology to 

mammalian GAP and is an important 

regulator of the Ras signal transduction 

pathway. To study the function of NF1 

in normal development and to develop 

a mouse model of NF1 disease, the 

inventors have used gene targeting in ES 

cells to generate mice carrying a null 

mutation at the mouse Nf1 locus. 

Although heterozygous mutant mice, 

aged up to 10 months, have not 

exhibited any obvious abnormalities, 

homozygous mutant embryos die in 

utero. Embryonic death is likely 

attributable to a severe malformation of 

the heart. Interestingly, mutant embryos 

also display hyperplasia of neural crestderived sympathetic ganglia. These 

results identify new roles for NF1 in 

development and indicate that some of 

the abnormal growth phenomena 

observed in NF1 patients can be 

recapitulated in neurofibromin-deficient 

mice. In addition, lethally-irradiated 

wild type mice transplanted with fetal 

liver cells taken from NF1 null embryos 

develop a form of juvenile chronic 

myelomonocytic leukemia (JMML) that 

is very similar to what is seen in 

children with NF1 disease. 

Applications 

• Research tool in studying some 

forms of human neuron diseases/ 

injuries in addition to juvenile chronic 

myelomonocytic leukemia (JMML). 

• Testing various therapeutic 

treatments for this disease. 

Inventors: Neal G. Copeland et al. 

(NCI). 

Patent Status: HHS Reference No. E– 

162–2004/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing under a Biological Materials 

License Agreement. 

Licensing Contact: Betty Tong, Ph.D.; 

301–594–6565; tongb@mail.nih.gov. 

Dated: May 27, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–12874 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 


PWALKER on PROD1PC71 with NOTICES
Federal Register / Vol. 74, No. 105 / Wednesday, June 3, 2009 / Notices 26711 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel; 2009 NIH Director’s Pioneer Award 

Interviews. 

Date: June 15–17, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Shan R. McCollough, 

Program Analyst, Division of Genetics and 

Developmental Biology, National Institute of 

General Medical Sciences, Building 45, 

Center Drive, Room 3AS13F, Bethesda, MD 

20892, 301–594–3555, 

smccollough@nigms.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: May 15, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–12230 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel; Environmental Sensors for 

Personal Exposure Assessment 

Administrative Meeting. 

Date: June 17, 2009. 

Time: 1 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIEHS Keystone, Keystone Park, 530 

Davis Drive, Durham, NC 27713 (Telephone 

Conference Call). 

Contact Person: RoseAnne M McGee, 

Associate Scientific Review Officer, 

Scientific Review Branch, Division of 

Extramural Research and Training, Nat. 

Institute of Environmental Health Sciences, 

P.O. Box 12233, MD EC–30, Research 

Triangle Park, NC 27709, (919) 541–0752, 

Mcgee1@niehs.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: May 26, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–12878 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group; Subcommittee 

F—Manpower & Training; NCI–F Manpower 

& Training Grants. 

Date: June 23–24, 2009. 

Time: 8 a.m. to 10 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Washington, DC, 

1515 Rhode Island Ave, Washington, DC 

20005. 

Contact Person: Lynn M. Amende, PhD, 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Blvd., Room 

8105, Bethesda, MD 20892, 301–451–4759, 

amendel@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: May 21, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–12880 Filed 6–2–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; ARRA SEP 

T32s. 

Date: June 24, 2009. 

Time: 10 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Washington DC, 

1515 Rhode Island Avenue, NW., 

Washington, DC, 20005. 

Contact Person: Lynn M Amende, PhD, 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Boulevard, Room 

8105, Bethesda, MD 20892–8328, 301–451– 

4759, amendel@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 


PWALKER on PROD1PC71 with NOTICES